Noxopharm Limited (NOX.AX)
AUD 0.09
(-1.06%)
AUD 0.09
(-1.06%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 2.4 Million | 6.01 Million | 5.42 Million | 5.6 Million | 8.28 Million | 3.75 Million |
| Cost of Revenue | 2.93 Million | 154.53 Thousand | 261.51 Thousand | 261.72 Thousand | 241.44 Thousand | 62.09 Thousand |
| Gross Profit | -534.81 Thousand | 5.85 Million | 5.16 Million | 5.34 Million | 8.04 Million | 3.68 Million |
| Operating Expenses | 7 Million | 16.44 Million | 14.94 Million | 14.34 Million | 16.12 Million | 15.6 Million |
| Selling, General and Administrative Expenses | 4.06 Million | 5.79 Million | 7.16 Million | 7.37 Million | 8.79 Million | 8.98 Million |
| Research and Development Expenses | 2.93 Million | 10.64 Million | 7.77 Million | 6.96 Million | 7.33 Million | 6.61 Million |
| Other Expenses | - | 1.55 Million | -3.42 Million | 13.95 Million | 19.91 Million | 3.57 Million |
| Cost and Expenses | 9.93 Million | 16.59 Million | 15.2 Million | 14.6 Million | 16.36 Million | 15.66 Million |
| Operating Income | -7.53 Million | -16.59 Million | -15.2 Million | -14.6 Million | -16.36 Million | -15.66 Million |
| Interest Expense | 31.16 Thousand | 40.99 Thousand | 77.33 Thousand | 2.19 Million | 3.46 Million | 667.2 Thousand |
| Income Tax Expense | -2.4 Million | -5.98 Million | -5.36 Million | 1.04 Million | -8.33 Million | -3.75 Million |
| Earnings before Tax | -5.97 Million | -21.04 Million | -24.03 Million | -8.3 Million | -8.23 Million | -16.32 Million |
| Net Income | -3.57 Million | -15.05 Million | -18.66 Million | -9.34 Million | -272.09 Thousand | -11.22 Million |
| Earnings Per Share Basic | -0.01 | -0.05 | -0.06 | -0.04 | -0.00 | -0.08 |
| Earnings Per Share Diluted | -0.01 | -0.05 | -0.06 | -0.04 | -0.00 | -0.08 |
| Weighted Average Shares Outstanding | 292.25 Million | 292.23 Million | 291.22 Million | 263.85 Million | 138.35 Million | 138.15 Million |
| Weighted Average Shares Outstanding (Diluted) | 292.23 Million | 292.23 Million | 291.22 Million | 263.85 Million | 138.35 Million | 138.15 Million |
| Gross Margin | -0.22 | 0.97 | 0.95 | 0.95 | 0.97 | 0.98 |
| EBIT Margin | -2.48 | -2.74 | -2.75 | -2.56 | -1.95 | -4.16 |
| Profit Margin | -1.49 | -2.51 | -3.44 | -1.67 | -0.03 | -2.99 |
| EBITDA | -5.94 Million | -20.84 Million | -23.69 Million | -5.84 Million | -4.52 Million | -15.59 Million |
| Earnings Before Tax Margin | -3.14 | -2.76 | -2.80 | -2.61 | -1.98 | -4.18 |
| Breakdown | 2024 Q4 | 2024 FY | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 1.18 Million | - | 1.21 Million | 2.66 Million | 6.01 Million | 3.34 Million |
| Cost of Revenue | 1.48 Million | 1743.00 | 876.00 | 11.04 Thousand | 154.53 Thousand | 143.49 Thousand |
| Gross Profit | -295.75 Thousand | -1743.00 | 1.21 Million | 2.65 Million | 5.85 Million | 3.2 Million |
| Operating Expenses | 3.53 Million | 7 Million | 3.46 Million | 7.61 Million | 16.44 Million | 8.82 Million |
| Selling, General and Administrative Expenses | 2.04 Million | - | 2.01 Million | 2.76 Million | - | 3.02 Million |
| Research and Development Expenses | 1.48 Million | - | 1.45 Million | 4.85 Million | - | 5.79 Million |
| Other Expenses | - | - | - | - | 1.55 Million | - |
| Cost and Expenses | 5.01 Million | 7 Million | 3.47 Million | 7.62 Million | 16.59 Million | 8.96 Million |
| Operating Income | -3.82 Million | -7 Million | -3.47 Million | -7.62 Million | -16.59 Million | -8.96 Million |
| Interest Expense | 4663.00 | 31.16 Thousand | 26.49 Thousand | 33.38 Thousand | 40.99 Thousand | 7607.00 |
| Income Tax Expense | -1.18 Million | -2.4 Million | -1.21 Million | -2.66 Million | -5.98 Million | -3.32 Million |
| Earnings before Tax | -1.08 Million | -5.97 Million | -3.7 Million | -12.29 Million | -21.04 Million | -8.74 Million |
| Net Income | -1.08 Million | -3.57 Million | -2.49 Million | -9.62 Million | -15.05 Million | -5.42 Million |
| Earnings Per Share Basic | -0.00 | - | -0.01 | -0.03 | - | -0.02 |
| Earnings Per Share Diluted | -0.00 | - | -0.01 | -0.03 | - | -0.02 |
| Weighted Average Shares Outstanding | 292.02 Million | 292.23 Million | 292.23 Million | 292.23 Million | 292.23 Million | 292.23 Million |
| Weighted Average Shares Outstanding (Diluted) | 292.23 Million | 292.23 Million | 292.23 Million | 292.23 Million | 292.23 Million | 292.23 Million |
| Gross Margin | -0.25 | - | 1.00 | 1.00 | 0.97 | 0.96 |
| EBIT Margin | -1.97 | - | -2.86 | -2.86 | - | -2.64 |
| Profit Margin | -0.91 | - | -2.06 | -3.61 | -2.51 | -1.62 |
| EBITDA | -2.34 Million | - | -3.46 Million | -7.61 Million | - | -8.82 Million |
| Earnings Before Tax Margin | -3.22 | - | -2.86 | -2.86 | -2.76 | -2.68 |
3002
000320
2121
MEDICO
FPH
9034